Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

November 30, 2011

Study Completion Date

January 31, 2012

Conditions
Non-Alcoholic Fatty Liver DiseaseNonalcoholic SteatohepatitisMetabolic Syndrome
Interventions
DRUG

Aramchol

100mg/d tablets packaged in bottles given orally once a day in the morning within 10 minutes after breakfast for a total period time of 3 months

DRUG

Aramchol

300 mg/d tablets packaged in bottles given orally once a day in the morning within 10 minutes after breakfast for a total period time of 3 months

DRUG

Placebo

tablets packaged in bottles given orally once a day in the morning within approximately 10 minutes after breakfast

Trial Locations (11)

13100

Safed Ziv Hospital, Safed

31096

Rambam, Haifa

34362

The Lady Davis Carmel Medical Center, Haifa

38100

Hillel Yaffe Medical Center, Hadera

44281

Meir Medical Center, Kfar Saba

49100

Belinson,Rabin Medical Center, Petah Tikva

64239

The Tel Aviv Sourasky Medical Center, Tel Aviv

76100

Kaplan M.C, Rehovot

84101

Soroka Medical Center, Beersheba

91120

Hadassah Ein Kerem M.C, Jerusalem

Unknown

Holy Family HOSPITAL, Nazareth

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Tel-Aviv Sourasky Medical Center

OTHER_GOV

collaborator

Beilinson Hospital, Petach Tikva,Israel

UNKNOWN

collaborator

Meir Medical Center

OTHER

collaborator

Kaplan Hospital ,Rehovot,Israel

UNKNOWN

collaborator

Soroka Hospital,Beer Sheva,Israel

UNKNOWN

collaborator

Hadassah Medical Organization

OTHER

collaborator

Hillel Yaffe Medical Center

OTHER_GOV

collaborator

Rambam Hospital, Haifa, Israel

UNKNOWN

collaborator

The Lady Davis Carmel Medical Center

UNKNOWN

collaborator

Holy Family Hospital, Nazareth, Israel

OTHER

collaborator

Ziv Hospital

OTHER_GOV

lead

Galmed Medical Reserch

INDUSTRY